Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis

• Status: Terminated
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis being tested is that inhibition of the enzyme known as elastase in the airways of patients with cystic fibrosis will help decrease the number of bacteria. Alpha1 antitrypsin, an elastase inhibitor, will be given to patients with cystic fibrosis by aerosol therapy twice in 1 day and sputum will be collected to measure the density of bacteria

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université de Sherbrooke
• Treatments: Alpha 1-Antitrypsin; Protein C Inhibitor

Criteria

Inclusion Criteria:

• Diagnosis of cystic fibrosis

• Age 14 years and older

• Women must have a negative pregnancy test and used effective contraception

• Must be able to produce sputum

• Sputum culture positive for Pseudomonas aeruginosa

Exclusion Criteria:

-